See today's BioWorld Asia
To read the full story, subscribe or sign in.

Kyocera pulls out of Regeneus deal for stem cell therapy Progenza for osteoarthritis

Feb. 7, 2023
By Tamra Sami
In a blow to Aussie regenerative medicine company Regeneus Ltd., Japan’s Kyocera Corp. has pulled out of a licensing deal for Regeneus’ lead mesenchymal stem cell (MSC) therapy, Progenza, for osteoarthritis of the knee for the Japan market.
BioWorld Asia Deals and M&A Inflammatory Australia Japan